Bahrain's health regulator on December 13 announced it has approved the registration of a COVID-19 vaccine developed by the China National Pharmaceutical Group, which is known as Sinopharm.

According to Bahrain News Agency, results from phase-3 clinical trials showed an 86-percent efficacy rate, a 99-percent seroconversion rate of neutralizing antibody, and 100-percent effectiveness in preventing moderate and severe COVID-19 cases.